Editorial
Targeted therapies in colorectal cancer: the dos, don’ts, and future directions
Journal of Gastrointestinal Oncology
2013;
4
(3)
:239-244
.
(11 September 2013)
Review Articles
Status of targeted therapies in the adjuvant treatment of colon cancer
Journal of Gastrointestinal Oncology
2013;
4
(3)
:245-252
.
(11 September 2013)
Understanding and targeting resistance to anti-angiogenic therapies
Journal of Gastrointestinal Oncology
2013;
4
(3)
:253-263
.
(11 September 2013)
The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers
Journal of Gastrointestinal Oncology
2013;
4
(3)
:264-284
.
(11 September 2013)
Integrating anti-EGFR therapies in metastatic colorectal cancer
Journal of Gastrointestinal Oncology
2013;
4
(3)
:285-298
.
(11 September 2013)
Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer
Journal of Gastrointestinal Oncology
2013;
4
(3)
:299-307
.
(11 September 2013)
Markers of resistance to anti-EGFR therapy in colorectal cancer
Journal of Gastrointestinal Oncology
2013;
4
(3)
:308-318
.
(11 September 2013)
A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers
Journal of Gastrointestinal Oncology
2013;
4
(3)
:319-327
.
(11 September 2013)
Targeted therapies in colorectal cancer: surgical considerations
Journal of Gastrointestinal Oncology
2013;
4
(3)
:328-336
.
(11 September 2013)
